Naomi B Haas MD, Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center September 22, 2018 at the…
Browsing: Kidney
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses the Management and Outcomes in…
Brian Shuch, MD Associate Professor of Urology Director, Kidney Cancer Program Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research…
Here, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, speaks at the 2018 Genitourinary Cancers Symposium, held in…
Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC,…
At the Genitourinary Cancers Symposium 2018 in San Francisco, CA, recent therapeutic developments for renal cell carcinoma (RCC) were discussed…
Michael Atkins, MD, of Georgetown University, Washington DC, outlines the results of the study of VEGF inhibitor axitinib in combination…
Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, gives an overview of a study (NCT02133742) looking at pembrolizumab…
Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC,…
Nataliya Mar, MD, UC Irvine Health, talks about Emerging New Agents for Urothelial Carcinoma | Immunotherapies in Metastatic Castration-Resistant Patients…
Nataliya Mar, MD, UC Irvine Health, talks about Phase 1 Urothelial Carcinoma Data Presented | Combination Therapies in Renal Cell…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Robert Figlin,…
Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates…
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic…
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients…
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic…
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in…
Primo N. Lara, Jr., MD, explains whether the TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable…
Primo N. Lara, Jr., MD, explains the convenience factor of oral TKIs influences decisions related to advanced renal cell carcinoma…
Exciting new data for metastatic renal cell carcinoma (mRCC) was presented at the American Society of Oncology (ASCO) 2018 Annual…
David I. Quinn, MD,the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options at the…
Primo N. Lara, Jr., MD, explains the trade-offs between safety and efficacy when considering 1st line renal cell carcinoma (RCC)…
David I. Quinn, MD, discusses whether the convenience factor of oral TKIs enters into the decision-making process when treating advanced…
Primo N. Lara, Jr., MD, explains how a newly diagnosed advanced renal cell carcinoma (RCC) patient should be treated in…
Primo N. Lara, Jr., MD, explains how he decides which metastatic renal cell carcinoma (mRCC) patients should receive a TKI…
David I. Quinn, MD, talks about which metastatic RCC patients should receive a TKI as first-line therapy.
David I. Quinn, MD, explains discusses Keynote 427 for Pembrolizumab, PD-1 Inhibitor and CTLA4 with Nivolumab & Ipilimumab presented at…
Primo N. Lara, Jr., MD, explains how how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell…
David I. Quinn, MD, shares his thoughts on the most interesting renal cell carcinoma (RCC) data being presented at the…
Jeanny B. Aragon-Ching, MD, FACP, discusses the 2nd line treatment options in RCC after I-O failure at Annual Meeting 2018.
Robert A. Figlin, MD, explains the convenience factor of oral TKIs & treatment decisions in advanced RCC
Robert A. Figlin, MD, explains the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
Robert A. Figlin, MD, talks about the best actions to take if newly diagnosed advanced renal cell carcinoma (RCC) patients…
Robert A. Figlin, MD, talks about how checkpoint inhibitors factor into 1st line RCC patient treatments.
Robert A. Figlin, MD, talks about Deciding which metastatic RCC patients should get a TKI as 1st line therapy.
Brian I. Rini, MD, Cleveland Clinic explains Anti-VEGF Therapy Has Been Standard | Field is Changing Dramatically at Annual Meeting…
Brian I. Rini, MD, Cleveland Clinic explains Combinations Being Developed for Kidney Cancer | Efficacy Will Drive Treatment Choices at…
Brian I. Rini, MD, Cleveland Clinic shares Patient Reported Outcomes Measure Tolerabilty | Trial Showed Benefits for Regimen Over Sunitinib…
Brian I. Rini, MD, Cleveland Clinic explains PR Results IMmotion151 Study | Progression-Free Survival & Encouraging Signals at Annual Meeting…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Focus on Potentially Predictive Markers | Neutrophil-to-Lymphocyte Ratio Blood Test May…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Clear Data for Nivolumab & Ipilimumab | In the Frontline for…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains New Combination Strategy for Metastatic RCC | Checkmate-214 Data for Nivolumab…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, Poor-Risk Patients Enrolled in Study for Surgery | Surgery is Not Significantly…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Lacking Data In Current Kidney Cancer Landscape | May Extrapolate Previous…
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains CARMENA Trial Randomized Patients | Either Tyrosine-Kinase Inhibitor, or Surgery &…
Saby George, MD, FACP, Roswell Park Cancer Institute, talks about CARMENA Study Showed Sunitnib Alone | Studies Showing Single-Agent Checkpoint…
Saby George, MD, FACP, Roswell Park Cancer Institute, shares CARMENA Study Results | Sunitinib Not Inferior to Sunitinib Following Nephrectomy…
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Checkmate-214 has a Higher Response Rate | 9% of Patients Went…
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination…
Saby George, MD, FACP, Roswell Park Cancer Institute, shares Checkmate-214 Not for All Kidney Cancer Patients | Study for Advanced…